Psychedelics as Medicines: An Emerging New Paradigm

  title={Psychedelics as Medicines: An Emerging New Paradigm},
  author={Devin M. Nichols and Mw Johnson and CD Nichols},
  journal={Clinical Pharmacology \& Therapeutics},
Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5‐HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with… 

New Paradigms of Old Psychedelics in Schizophrenia

There is a need to dig deeply into psychedelic neurobiology to uncover how psychedelics could best be used as scientific tools to benefit psychiatric disorders including schizophrenia.

From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders

Recent findings and information on how psychedelics may act therapeutically on cells within the central nervous system (CNS) during brain injuries and neurodegenerative diseases are discussed.

Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

This chapter is devoted to illuminating and discussing questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new.

Psychedelic‐inspired approaches for treating neurodegenerative disorders

Evidence suggests that psychedelics and related compounds could prove useful for treating the behavioral and psychological symptoms of dementia (BPSD), and the robust effects of these compounds on structural and functional neuroplasticity and inflammation clearly warrant further investigation.

Psychedelic Drugs in Biomedicine.

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.

The aim of this review is to examine the current standing of evidence regarding psychedelic psychopharmacology and to provide an overview of the use and effectiveness of these drugs in the treatment of SUD, alcohol use disorder, and for smoking cessation.

Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.

Current understanding of the biochemical signaling pathways activated by psychedelics and related neuroplasticity-promoting molecules are reviewed, with an emphasis on key unanswered questions.




  • D. Nichols
  • Psychology, Biology
    Pharmacological Reviews
  • 2016
Blood oxygen level–dependent functional magnetic resonance imaging and magnetoencephalography have been employed for in vivo brain imaging in humans after administration of a psychedelic, and results indicate that intravenously administered psilocybin and LSD produce decreases in oscillatory power in areas of the brain’s default mode network.

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report.

OBJECTIVES Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Three complementary neuroimaging techniques, implemented during resting state conditions, revealed marked changes in brain activity after LSD that correlated strongly with its characteristic psychological effects, contributing important new insights into the characteristic hallucinatory and consciousness-altering properties of psychedelics.

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

A single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data, providing a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms.

Human hallucinogen research: guidelines for safety

The unique history of human hallucinogens research is discussed, the risks of hallucinogen administration and safeguards for minimizing these risks are reviewed, and carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety and revealed a positive trend toward improved mood and anxiety.

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Psilocybin caused a significant decrease in the positive coupling between the mPFC and PCC, which strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector hubs, enabling a state of unconstrained cognition.